Literature DB >> 26309702

Long-term unexpected consequence of two kidney transplants with full-match grafts: a report of two cases.

Erhan Tatar1, Adam Uslu2, Ahmet Aykas2, Tamer Sahin3.   

Abstract

HLA typing is the cornerstone of kidney transplantation. Here, we present two full-match kidney transplants with early uneventful course but late c4d-mediated rejection and recurrent pauce-immune necrotizing crescentic glomerulonephritis, as each in one. Case 1: A 49 years old Caucasian female patient, received a six-matched cadaveric kidney and had nonspecific changes in 6th and 12th month protocol biopsies. The first and third year serum creatinin value was 1.8 and 2.0 mg/dl. Immunosuppressive drugs were gradually reduced due to recurrent infections at the 3rd year. She admitted with allograft dysfunction and serum creatinin 5.8 mg/dl. Kidney biopsy of graft dysfunction at the 4th year was diagnosed C4d-mediated rejection. Case 2: A 61 years old Caucasian female patient received a HLA-identical kidney 8.5 years ago from her sibling had a primary vasculitis mediated necrotizing crescentic glomerulonephritis. Her serum creatinin values in the 1st and 8th years were 1.3 and 1.7 mg/dl. In recent years, immunosuppressive dosage has been gradually reduced due to recurrent lower respiratory tract infections. She admitted with hematuria, purpuric rash, dyspnea. and serum creatinin 5.7 mg/dl. Renal biopsy revealed necrotizing crescentic glomerulonephritis. The patient was treated with pulse steroid, double filtration plasmapheresis and rituximab. She is being followed with a functioning graft and with serum creatinin 2.0 mg/dl. In case of recurrent infection, immunosuppressive drugs should be modified cautiously even in patients with full-match grafts to prevent late acute rejection or recurrence of the primary disease.

Entities:  

Keywords:  Full match; kidney transplantation; late rejection; necrotizing crescentic glomerulonephritis; rituximab

Year:  2015        PMID: 26309702      PMCID: PMC4537997     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  18 in total

1.  Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation.

Authors:  S K Takemoto; P I Terasaki; D W Gjertson; J M Cecka
Journal:  N Engl J Med       Date:  2000-10-12       Impact factor: 91.245

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 3.  HLA matching for kidney transplantation.

Authors:  Steve Takemoto; Friedrich K Port; Frans H J Claas; Rene J Duquesnoy
Journal:  Hum Immunol       Date:  2004-12       Impact factor: 2.850

4.  Twenty-year follow-up on the effect of HLA matching on kidney transplant survival and prediction of future twenty-year survival.

Authors:  P I Terasaki; Y Cho; S Takemoto; M Cecka; D Gjertson
Journal:  Transplant Proc       Date:  1996-06       Impact factor: 1.066

5.  The effect of HLA-C matching on acute renal transplant rejection.

Authors:  C Frohn; L Fricke; J C Puchta; H Kirchner
Journal:  Nephrol Dial Transplant       Date:  2001-02       Impact factor: 5.992

6.  Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant.

Authors:  Christine Murakami; Pradeep Manoharan; Naima Carter-Monroe; Duvuru Geetha
Journal:  Transpl Int       Date:  2013-10-18       Impact factor: 3.782

7.  The HLA-matching effect in different cohorts of kidney transplant recipients: 10 years later.

Authors:  Nori Sasaki; Adam Idica
Journal:  Clin Transpl       Date:  2010

8.  Successful induction of remission with rituximab for relapse of ANCA-associated vasculitis post-kidney transplant: report of two cases.

Authors:  D Geetha; P Seo; U Specks; F C Fervenza
Journal:  Am J Transplant       Date:  2007-10-01       Impact factor: 8.086

9.  Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression.

Authors:  M Gera; M D Griffin; U Specks; N Leung; M D Stegall; F C Fervenza
Journal:  Kidney Int       Date:  2007-04-04       Impact factor: 10.612

10.  Long-term mycophenolate monotherapy in human leukocyte antigen (HLA)-identical living-donor kidney transplantation.

Authors:  Blanca Gascó; Ignacio Revuelta; Ana Sánchez-Escuredo; Miquel Blasco; Federico Cofán; Nuria Esforzado; Luis F Quintana; María José Ricart; José Vicente Torregrosa; Josep M Campistol; Federico Oppenheimer; Fritz Diekmann
Journal:  Transplant Res       Date:  2014-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.